Corporate Satellite Symposia and Education Theater Schedule

CME Satellite Lunch Symposium

Learning Objectives:

1.  Describe the clinical features, diagnostic criteria, and natural history of NF1 and associated PNs in pediatric patients
2. Summarize the latest evidence supporting the use of MEK inhibitors in pediatric patients with NF1-PN
3. Develop evidence-informed, personalized treatment plans with MEKi therapy for pediatric patients with NF1-PN
4. Implement team-based strategies to optimize patient education, referral pathways, toxicity management, and longitudinal care for patients with NF1-PN

Faculty: Potential Chair and Faculty Member include, but are not limited to:

• Amy Armstrong, MD, Washington University School of Medicine
• Jaishri Blakeley, MD, Johns Hopkins University School of Medicine
• Miriam Bornhorst, MD, Ann & Robert H. Lurie Children’s Hospital; Stanley Manne Children’s Research Institute
• Alice P. Chen, MD, National Cancer Institute
• Rosalie E. Ferner, MD, FRCP, Guy’s and St. Thomas’ NHS Foundation
• Michael J Fisher, MD, Children’s Hospital of Philadelphia
• Andrea M. Gross, MD, National Cancer Institute
• Angela Hirbe, MD, Washington University School of Medicine
• Laura Klesse, MD, PhD, UT Southwestern Medical Center
• Bruce Korf, MD, PhD, The University of Alabama at Birmingham
• Carlos Romo, MD, Johns Hopkins University
• Aimee Sato, MD, Seattle Children’s UW Medicine

Synopsis of the Program:

This program, developed in collaboration with NF Network, will use case-based dialogue between NF1 experts to provide a framework for diagnosing NF1 and PNs in pediatric patients, incorporating MEKi therapy, and capturing tumor progression/response, while highlighting important aspects of personalized care planning that call for collaborative team interventions.

Supported by: Alexion Pharmaceuticals and SpringWorks
Organization providing logistical/meeting support: PVI, PeerView Institute for Medical Education
Room: TBD

Desire for Dialogue: Initiating the patient conversation about cancer treatment, sexuality, and fertility.

(CME non-CME) Satellite Lunch Symposium

Abstract:

It is up to us to make the first move. Talking about sexual health or fertility issues with a clinician is fairly uncomfortable for many; now imagine how hard it is for people with cancer. With all the perplexing and competing priorities to discuss, the chance of patients initiating topics of sex and intimacy are slim. This presentation is designed to make that conversation easier, it contains suggestions for you to help patients better understand how cancer could affect their fertility and sexuality and what they can do about it.

Learning Objectives:

1. Review the current landscape on sexual health and fertility in patients with cancer.
2. Discuss the patient related and provider related barriers to providing care around sexual health and fertility issues.
3. Identify strategies to provide education and support to patients concerned about or experiencing sexual health or fertility issues.

Speaker(s): Kristen Mendez, MSN, APRN, CPNP-AC, CPHON, BMTCN, NE-BC, NPD-BC
Sponsored by: Servier Pharmaceuticals, LLC

Learning Objectives:

1. Discuss barriers to care, guidelines, and clinical evidence supporting the use of recombinant Erwinia-derived asparaginase for pediatric and AYA patients with ALL/LBL
2. Adapt team-based management plans to include alternative Erwinia-derived asparaginase for pediatric and AYA patients with ALL/LBL, as informed by the monitoring of hypersensitivity and other adverse developments
3. Employ collaborative care protocols to address practical aspects of Erwinia-derived asparaginase, including flexible dosing, therapeutic vigilance, and safety managemen

Faculty: Potential Chair and Faculty Member include, but are not limited to:

• Rachel A. Egler, MD; Case Western Reserve University School of Medicine
• Luke Maese, DO; University of Utah Health
• Michael J Burke, MD; Medical College of Wisconsin
• Elizabeth A. Raetz, MD; NYU Langone Health
• Rachel Rau, MD; University of Washington, Seattle Children's Hospital
• Lewis B. Silverman, MD; Dana-Farber Cancer Institute

Synopsis of the Program:

This Clinical Consults program uses expert-led cases and mini-lectures to review asparaginase’s central role in ALL/LBL therapy, challenges with toxicity and inactivation, recognition of hypersensitivity, evidence for recombinant Erwinia and new dosing strategies, sequential treatment planning for pediatric/AYA patients, and best practices for monitoring serum activity and ensuring safe, uninterrupted therapy.

Accredited Provider: PVI, PeerView Institute for Medical Education and Supported by Jazz Pharmaceuticals
Room: TBD

von Willebrand disease- prophylaxis for all

Non-CME Satellite Breakfast Symposium

Learning Objectives:

1. Understand the benefits of prophylaxis in patients with von Willebrand disease including children younger than 6 years of age

Faculty: To Be Determined

Synopsis of the Program:

von Willebrand disease causes bleeding episodes that negatively impact patients’ quality of life and put them at risk for iron deficiency. Prophylaxis can reduce bleeding episodes across all types of von Willebrand disease and bleeding sites.

Supported by: Octapharma
Room: TBD

12:00 PM – 1:15 PM

Learning Objectives:

1. Review the challenges associated with managing patients with pLGG
2. Explore the role of MAPK pathway inhibition in the clinical management of pLGG
3. Review updated clinical efficacy and safety profile of a Type II RAF inhibitor
4. Discuss hypothetical patient cases with R/R pLGG

Faculty:

• TBD

Supported by: Day One Biopharmaceuticals, Inc
Room: TBD

Learning Objectives:

1. Describe the pathophysiology of VWD and mechanisms of von Willebrand factor relevant to the presentation in pediatric patients
2. Differentiate between recombinant and plasma-derived VWF products, incorporating PK/PD considerations into individualized treatment selection for pediatric patients
3. Integrate evidence-based strategies to individualize treatment plans for pediatric patients with VWD

Faculty: TBD

Synopsis of the Program:

Children with von Willebrand disease (VWD) often experience delayed diagnosis, non-individualized treatment, and poor management of comorbid bleeding symptoms, such as heavy menstrual bleeding, recurrent epistaxis (nosebleeds), and anemia. This session aims to improve the pediatric hematology team’s knowledge, confidence, and skills related to caring for patients with confirmed or suspected pediatric VWD.

Accredited provider: This activity is jointly provided by The France Foundation and the International Society on Thrombosis and Haemostasis (ISTH).

Supported by: Takeda

Credit designation:

• Physicians: The France Foundation designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• Nurses: The France Foundation designates this activity for 1.25 contact hours.
• Physician Assistants: The France Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
• All other health care professionals completing this course will be issued a statement of participation.

Room: TBD